Alzheimer disease 16
MONDO:0010422
An Alzheimer's disease that is characterized by an associated with a risk allele in in the PCDH11X gene on chromosome Xq21.3.
Disease research snapshot
CureCurrent currently links 2 distinct registered clinical trials to Alzheimer disease 16 through its MONDO disease mappings. 0 of those studies have the registry status “recruiting” (0%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.
The leading sponsor shown in this linked dataset is Cognito Therapeutics, Inc., associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.
The highest-count mapped research city in the current result is Albany, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.
Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Alzheimer disease 16
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
2 shownDrugs being studied
Research locations
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.